Table 2.
Univariable comparison of demographic and disease characteristics of patients who received physical vs teleconsultation
| Physical consultation visits (n = 343) |
Teleconsultation visits (n = 92) |
P | |
|---|---|---|---|
| Age, mean (S.d.) | 46.2 (13.9) | 40.0 (12.1) | 0.01 |
| Current disease duration in years, median (IQR) | 10.3 (3.8–16.8) | 12.3 (6.4–18.2) | 0.14 |
| Current SLEDAI-2K, mean (S.d.) | 2.8 (2.7) | 2.0 (1.9) | 0.04 |
| SLEADI-2k at last visit, mean (S.d.) | 2.7 (2.6) | 2.4 (2.3) | 0.44 |
| SDI, median (IQR) | 0 (0–2) | 0 (0–1) | 0.39 |
| Current prednisolone, n (%) | 246 (71.7) | 49 (53.3) | <0.01 |
| Prednisolone at last visit, n (%) | 253 (73.8) | 51 (55.4) | <0.01 |
| Flare at current visit, n (%) | 33 (9.6) | 2 (2.2) | 0.02 |
| Flare at last visit, n (%) | 45 (13.1) | 4 (4.3) | 0.02 |
| Immunosuppression at this visita, n (%) | 256 (74.6) | 65 (70.7) | 0.50 |
IQR: interquartile range; SLEDAI-2k: Systemic Lupus Erythematosus Disease Activity Index -2K; SDI: Systemic Lupus Erythematosus Collaborating Clinics Damage Index.
a
Includes AZA, MMF, rituximab, CYC, belimumab, ciclosporin, tacrolimus, MTX and LEF.